



**Iowa Medicaid Drug Utilization Review (DUR) Commission Meeting
June 3, 2009**

**Location: Learning Resource Center
3550 Mills Civic Parkway
West Des Moines, Iowa**

Time: 9:30 a.m. – 1:30 p.m.

Tentative Agenda

1. Welcome & Introductions
 - a) Commission Members and Staff
 - b) Approval of the minutes
2. Iowa Medicaid Enterprise Update(s)
3. New Policy on Literature Cited During Public Comment – Discussion
4. Case Reviews
5. Public Comment (See Conflict of Interest Disclosure Form)
6. Prior Authorization
 - a) Modified Formulations Prior Authorization Criteria
 - b) Extended Release Formulations Prior Authorization Criteria
 - c) ADD/ADHD/Narcolepsy Agents
 - d) Nonsteroidal Anti-Inflammatory Drugs
 - e) Thrombopoeitin Receptor Agonists
 - f) Polyethylene Glycol 3350 – Programming
7. Public Comment (See Conflict of Interest Disclosure Form)
8. Focus Studies/Provider Education Initiatives
 - a) Multiple Antipsychotic Use in Children – Second Follow Up
 - b) Chronic *Bactroban* Use – Follow Up
 - c) Duplicate NSAIDs (including topical diclofenac) Initial Review
 - d) *Synagis* Utilization – Initial Review
 - e) Proton Pump Inhibitors plus *Plavix* – Initial Review
 - f) Benzodiazepines without SSRI/SNRI – Initial Review
 - g) Impact of Methadone Conversion & Dosing Information – Initial Review
 - h) *Subutex/Suboxone* plus Narcotics – Initial Review

9. Miscellaneous

- a) DUR Digest (Draft) 2009 Volume 21, Number 3
- b) SMAC Update
- c) FUL Update
- d) MedWatch

10. Executive Closed Session

- a) Approval of Minutes
- b) Review of Focus Studies Data with PHI
- c) Member Profiles

11. Adjournment

Individuals attending meetings of the DUR Commission shall have an opportunity to address the Commission. This opportunity will be granted twice during the open portion of the meeting. In order to accommodate all interested parties, all speakers are requested to limit their comments to **5 minutes or less**. If you represent a drug manufacturer as an employee, as a contractor, as a member of the manufacturer's Speaker Bureau, or by any other means, we expect you to cover your individual product or entire product line in that five-minute time frame. Speakers who represent multiple manufacturers will share their 5 minutes with the other manufacturer representative(s) whose product they are speaking on.

www.iadur.org

For more information contact the DUR Director, Chad Bissell, Pharm.D. at info@iadur.org or (515) 725-1271